Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Ambrx, MabSpace in ADC deal

    Ambrx Inc. (La Jolla, Calif.) and MabSpace Biosciences Co. Ltd. (Suzhou, China) said they plan to discover and develop antibody-drug conjugates for oncology. The partners will use MabSpace's humanized antibody …

    Published on 1/5/2017
  • COMPANY NEWS: J&J reveals spate of partnerships

    The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled a series of new partnerships Thursday, including collaborations in cancer, immunotherapy, and non-alcoholic steatohepatitis (NASH).Among the…

    Published on 1/5/2017
  • COMPANY NEWS: Lilly restructures commercial organization

    Just days after new President and CEO David Ricks took the reins, Eli Lilly and Co. (NYSE: LLY) announced changes to its commercial leadership and organization, including the departure of Alex Azar as president of Lilly…

    Published on 1/5/2017
  • COMPANY NEWS: Priority Review for Melinta's anti-infective

    Melinta Therapeutics Inc. (New Haven, Conn.) said FDA accepted and granted Priority Review to NDAs for IV and oral Baxdela delafloxacin to treat acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA …

    Published on 1/5/2017
  • COMPANY NEWS: Arena sells off Belviq rights

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA) said it amended its licensing agreement with Eisai Co. Ltd. (Tokyo:4523), granting the Japanese pharma worldwide development and commercialization rights to obesity drug Belviq …

    Published on 1/4/2017
  • COMPANY NEWS: Management tracks

    Cancer company Infinity Pharmaceuticals Inc. (NASDAQ:INFI) said President of R&D Julian Adams will retire, effective Jan. 6. The company promoted Lawrence Bloch to president from CFO. The company also promoted Claudio …

    Published on 1/4/2017
  • COMPANY NEWS: Venter handing off CEO role at Human Longevity

    J. Craig Venter will step down as CEO of Human Longevity Inc. (San Diego, Calif.), effective Jan. 9. He will remain executive chairman of HLI, which he co-founded in 2013.Cynthia Collins will succeed Venter as CEO. She …

    Published on 1/4/2017
  • COMPANY NEWS: CymaBay grants Kowa U.S. rights to gout candidate

    CymaBay Therapeutics Inc. (NASDAQ:CBAY) granted the Kowa Pharmaceuticals America Inc. subsidiary of Kowa Co. Ltd. (Nagoya, Japan) rights in the U.S. to arhalofenate (MBX-102), which is in development to treat gout. …

    Published on 1/3/2017
  • COMPANY NEWS: Luoxin, Yuhan fail to complete deal for NSCLC therapy

    Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (HKSE:8058) said it was unable to complete a deal with Yuhan Corp. (KSE:000100) that would have granted Luoxin rights to YH25448, which is in preclinical testing to …

    Published on 1/3/2017
  • COMPANY NEWS: Management tracks

    RNA therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said SVP and CBO David-Alexandre Gros will resign for personal reasons, effective Jan. 6. The company is searching for a replacement. Alnylam also …

    Published on 1/3/2017
  • COMPANY NEWS: Biogen prices Spinraza

    Biogen Inc. (NASDAQ:BIIB) priced spinal muscular atrophy (SMA) drug Spinraza nusinersen at a wholesale acquisition cost (WAC) of $125,000 per vial, spokesperson Matt Fearer told BioCentury. Based on Spinraza's dosing …

    Published on 12/30/2016
  • COMPANY NEWS: Cempra hammered on CRL for Solithera

    Cempra Inc. (NASDAQ:CEMP) shares lost more than half their value this week after the company received a complete response letter from FDA for its NDAs for oral and IV Solithera solithromycin to treat community acquired …

    Published on 12/30/2016
  • COMPANY NEWS: China accepts NDA for Ascletis' HCV candidate

    Ascletis Pharmaceuticals Co. Ltd. (Shaoxing, China) said China FDA accepted for review an NDA for danoprevir (ASC08) to treat HCV infection. The company obtained Chinese rights to the HCV NS3/4A protease inhibitor from …

    Published on 12/30/2016
  • COMPANY NEWS: Dong-A grants AbbVie rights to MERTK inhibitor

    Dong-A ST Co. Ltd. (KSE:170900) granted AbbVie Inc. (NYSE:ABBV) exclusive rights outside South Korea to a c-Mer proto-oncogene tyrosine kinase (MERTK) inhibitor that is in preclinical development to treat cancer.The …

    Published on 12/30/2016
  • COMPANY NEWS: Hanmi, Sanofi amend diabetes deal

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) announced changes to a blockbuster November 2015 deal that had granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to three diabetes treatments in Hanmi's "…

    Published on 12/30/2016
  • COMPANY NEWS: Mallinckrodt buys into Mesoblast in cell therapy deal

    Mallinckrodt plc (NYSE:MNK) acquired a 5% stake in Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) and obtained exclusive negotiation rights for two cell therapy candidates to treat low back pain and graft-versus-host disease (…

    Published on 12/23/2016
  • COMPANY NEWS: Portola jumps on Priority Review for betrixaban

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA) gained $6.33 (34%) to $25.06 after it said FDA accepted and granted Priority Review to the biotech's NDA for betrixaban (PRT054021) for extended-duration prophylaxis of venous …

    Published on 12/23/2016
  • COMPANY NEWS: Biocartis submits Idylla to FDA, partners with Amgen

    Biocartis Group N.V. (Euronext:BCART) said it submitted molecular diagnostics platform Idylla to FDA via the 510(k) pathway. Separately, the company announced a deal with Amgen Inc. (NASDAQ:AMGN) to evaluate Ras …

    Published on 12/22/2016
  • COMPANY NEWS: Management tracks

    As part of a restructuring, fertility company OvaScience Inc. (NASDAQ:OVAS) said President and CEO Harald Stock and COO Paul Chapman will leave the company. OvaScience is also reducing headcount by about 30%, slowing …

    Published on 12/22/2016
  • COMPANY NEWS: PharmaMar, Chugai in second cancer deal

    PharmaMar S.A. (Madrid:PHM) said it granted Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) rights in Japan to lurbinectedin (PM1183). The candidate is in Phase III studies to treat two forms of cancer. PharmaMar added EUR …

    Published on 12/22/2016
  • COMPANY NEWS: Vifor, ChemoCentryx expand kidney partnership

    ChemoCentryx Inc. (NASDAQ:CCXI) and the Vifor Pharma Ltd. subsidiary of Galenica Ltd. (SIX:GALN) said they will expand their kidney disease partnership to include ChemoCentryx candidate CCX140, an inhibitor of CC …

    Published on 12/22/2016
  • COMPANY NEWS: Actelion, J&J back in takeout talks

    Actelion Ltd. (SIX:ATLN) said Wednesday it is in exclusive negotiations with Johnson & Johnson (NYSE:JNJ) about a possible deal. The Swiss biotech acknowledged in late November that J&J had approached it about a …

    Published on 12/21/2016
  • COMPANY NEWS: BioInvent, Pfizer in cancer antibody deal

    BioInvent International AB (SSE:BINV) gained SEK0.63 (32%) to SEK2.63 after announcing a partnership with Pfizer Inc. (NYSE:PFE) to develop antibodies against tumor-associated myeloid cells.BioInvent will receive …

    Published on 12/21/2016
  • COMPANY NEWS: Caforio to become BMS chairman

    Bristol-Myers Squibb Co. (NYSE:BMY) said CEO Giovanni Caforio will succeed Lamberto Andreotti as chairman, effective May 2. Andreotti is retiring.Caforio will remain CEO. He succeeded Andreotti in that role in May 2015…

    Published on 12/21/2016
  • COMPANY NEWS: CRL for Advanced Accelerator's Lutathera

    Advanced Accelerator Applications S.A. (NASDAQ:AAAP) said FDA issued a complete response letter for Lutathera (177-Lu-Dotatate) to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The company …

    Published on 12/21/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993